Harris B, Wong G, Skolnick P
Laboratory of Neuroscience, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
J Pharmacol Exp Ther. 1993 Jun;265(3):1392-8.
Pharmacologically relevant concentrations of inhalational anesthetics such as halothane, enflurane and isoflurane enhance [3H]flunitrazepam (FLU) binding to benzodiazepine receptors prepared from well-washed membranes of murine cerebral cortex and cerebellum. These effects were concentration dependent and markedly enhanced by addition of chloride to the incubation medium. Using halothane as a prototype inhalational agent, it was observed that like barbiturates, increases in [3H]FLU binding were effected through an increase apparent in the apparent affinity of this radioligand with no accompanying change in the maximum number of binding sites. Although previous reports have demonstrated barbiturates augment gamma-aminobutyric acid-enhanced [3H]benzodiazepine binding, halothane exerts an additive effect in the nominal absence of chloride. Isoflurane produces a significant reduction in the EC50 of pentobarbital-augmented [3H]FLU binding. Halothane modestly reduced the binding of a benzodiazepine receptor inverse agonist, [3H]Ro 15-4513. Significant differences were also observed in the potencies and efficacies of both isoflurane and enflurane to enhance [3H]FLU binding to benzodiazepine receptors in cerebellar and cortical membranes. These findings provide a possible molecular basis for the clinical observation that benzodiazepines and barbiturates augment the anesthetic properties of inhalational agents. Moreover, the regional differences in anesthetic potency and efficacy reported here suggest a differential interaction of these inhalational agents among gamma-aminobutyric acidA receptor isoforms.
